G-Protein Coupled Receptors Market by Receptor Class (Class A Rhodopsin, Class B Secretin, Class C Metabotropic Glutamate), Therapeutic Area (Cardiovascular Diseases, Cns Disorders, Gastrointestinal Disorders), Application, End User - Global Forecast 2025
Description
The G-Protein Coupled Receptors Market was valued at USD 3.91 billion in 2024 and is projected to grow to USD 4.23 billion in 2025, with a CAGR of 9.58%, reaching USD 8.15 billion by 2032.
How converging breakthroughs in structural biology, computational modeling, and translational platforms are reshaping GPCR therapeutic strategies and program prioritization
The field of G-protein coupled receptors (GPCRs) sits at a pivotal inflection point where basic discovery converges with translational ambition. Over the past decade, incremental advances in structural biology, cryo-electron microscopy, and high-resolution ligand screening have converged with computational modeling and phenotypic screening to create a more navigable target landscape. As a result, drug discovery teams are moving beyond traditional orthosteric antagonism toward nuanced modulation strategies that include biased agonism, allosteric modulation, and ligand-directed signaling. These shifts are not merely technical; they are reshaping therapeutic hypotheses and enabling new modality classes to enter early development.
In parallel, the ecosystem supporting GPCR research has matured. Contract research organizations, academic centers, and specialized diagnostic labs are deploying integrated platforms to accelerate target validation and compound progression. This has increased the throughput of translational pipelines and shortened the interval between target identification and clinical testing. Consequently, stakeholders must adapt both scientific frameworks and operational models to capture value. Investment decisions now hinge on the ability to translate molecular insights into clinically meaningful endpoints, while navigating regulatory expectations and payer scrutiny. The interplay of enabling technologies, collaborative frameworks, and strategic prioritization defines the contemporary GPCR narrative and will determine which programs advance most successfully into late-stage development.
Key technological, translational, and commercial inflection points that are fundamentally altering GPCR program strategies and collaborative models across drug development
The GPCR landscape is experiencing transformative shifts driven by several catalytic forces that together redefine competitive advantage. First, technological maturation in structural and biophysical methods has unlocked receptor conformations previously inaccessible, prompting discovery teams to revisit long-dormant target classes and to design more selective modulators. Second, advances in single-cell and spatial omics are providing richer disease context and receptor expression maps, allowing researchers to prioritize targets with clearer mechanistic links to clinical phenotypes. Third, the rise of precision medicine frameworks has elevated the importance of biomarkers and companion diagnostics, which are increasingly integrated into early-phase programs to derisk late-stage development.
These trends are accompanied by evolving modality mixes, where small molecules, peptides, and biologics are complemented by innovative delivery approaches and intracellular targeting strategies. The commercial landscape is also shifting as partnerships between biopharma and specialized technology providers accelerate, and as investors place a premium on programs that demonstrate differentiated mechanisms or clear paths to biomarker-driven endpoints. Together, these dynamics are reshaping priorities across discovery, preclinical development, and clinical trial design, and they are prompting organizations to reassess talent, infrastructure, and partnership models to remain competitive in a rapidly evolving field.
Anticipating how tariff-driven shifts to supply chains, procurement choices, and clinical operations will influence GPCR program timelines and strategic sourcing decisions
The introduction of tariffs and changes to trade policy can exert multifaceted effects on the lifecycle of GPCR-focused programs, with consequences that ripple from procurement through clinical operations. Increased tariffs on imported reagents, laboratory instrumentation, and specialized consumables can raise operational costs for discovery and preclinical labs, prompting procurement teams to explore alternative suppliers, to accelerate inventory hedging, or to localize sourcing to mitigate exposure. These procurement dynamics can, in turn, influence the timing and throughput of screening campaigns and in vivo studies.
For clinical development, tariffs that affect the cost or availability of devices, diagnostic reagents, or outsourced services can complicate global trial execution and site selection. Sponsors may face higher per-patient operational costs, longer lead times for specialized equipment, and increased complexity in managing cross-border logistics for biological samples. CROs and service providers confronted with elevated input costs may pass these onto sponsors or restructure contracts, adding negotiation friction and potentially altering program budgets and timelines.
Longer term, tariff-driven cost pressures can incentivize reshoring of manufacturing and support services, investment in domestic supply chains, and consolidation among vendors that can absorb incremental costs. While tariff policy is only one of several factors shaping program economics, it materially alters strategic deliberations around outsourcing, localization, and portfolio sequencing for teams advancing GPCR-targeted therapies into clinical development.
Detailed segmentation insights that connect receptor classes, therapeutic focus areas, development applications, and end-user profiles to strategic research and commercial priorities
Segment-level granularity illuminates where scientific opportunity and commercial necessity intersect within the GPCR ecosystem. Analysis by receptor class highlights the prominence of Class A rhodopsin receptors, which are explored through subtypes such as amino acid receptors, chemokine receptors, lipid receptors, monoamine receptors, opsin receptors, and peptide receptors, while Class B secretin, Class C metabotropic glutamate, Class F frizzled/taste 2, and orphan receptors expand the horizon for novel mechanisms. This receptor-centric framework supports target prioritization by correlating structural tractability, disease linkage, and historical success rates.
Therapeutic area segmentation underscores the breadth of clinical applications for GPCR modulation, from cardiovascular diseases and central nervous system disorders to gastrointestinal illness, inflammatory conditions, metabolic disorders, oncology, pain management, and respiratory disease, with oncology programs further differentiated into areas such as breast cancer, colorectal cancer, leukemia, lung cancer, and prostate cancer. Mapping receptors to therapeutic indications clarifies where translational investability is strongest and where biomarker strategies are most critical.
Application-based segmentation captures the lifecycle of innovation, spanning drug discovery, preclinical development, diagnostics, and clinical trials across early to late phase development, and highlights how phase-specific needs-such as validation assays or companion biomarker deployment-shift resource allocation. Finally, end-user segmentation differentiates academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotech companies, offering insight into where demand for specialized services, platform technologies, and collaborative partnerships will concentrate as programs advance through discovery and development.
How regional capabilities, regulatory frameworks, and clinical infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific shape GPCR development and commercialization strategies
Regional dynamics shape the strategic choices of GPCR programs as scientific opportunity intersects with regulatory regimes, healthcare infrastructure, and investment ecosystems. In the Americas, a concentration of innovation hubs, advanced clinical research networks, and deep capital markets supports rapid progression from discovery to late-stage trials, while a mature biotech and pharmaceutical sector drives demand for specialized CROs, diagnostics, and translational services. This environment favors bold translational hypotheses and the rapid scaling of clinical programs when regulatory and reimbursement planning is integrated early.
Europe, the Middle East & Africa presents a heterogeneous landscape in which strong academic centers and industry clusters coexist with varied regulatory pathways and market access frameworks. Cross-border collaborations and pan-regional clinical trial designs are common, and the region often serves as a testing ground for biomarker-driven development strategies that require sophisticated diagnostics. Meanwhile, Asia-Pacific exhibits rapid growth in R&D investment, an expanding talent base, and increasing capabilities in both discovery and manufacturing. Emerging markets in this region can offer cost-effective clinical trial capacity and manufacturing scale, yet stakeholders must carefully navigate local regulatory expectations and infrastructure variances.
These regional contrasts inform decisions about site selection, partnership models, and commercialization sequencing, and they emphasize the need for a nuanced approach that aligns scientific objectives with regional capabilities and patient access considerations.
Corporate and partnership strategies that combine platform investments, biomarker integration, and agile portfolio management to accelerate GPCR discoveries toward clinical proof of concept
Companies operating across the GPCR value chain are differentiating through technology stacks, therapeutic focus, and strategic partnerships. Large pharmaceutical firms leverage broad internal capabilities to advance late-stage programs and to integrate companion diagnostics with clinical development, while nimble biotech companies often pursue high-risk, high-reward targets enabled by specialized platforms or novel modality approaches. Contract research organizations and diagnostic laboratories emphasize integrated service offerings, combining assay development, biomarker analytics, and clinical support to accelerate program timelines and reduce translational uncertainty.
Strategic collaborations are a central theme, as biopharma organizations seek external expertise in structural biology, AI-driven discovery, and specialized assay development to complement internal strengths. Investment in platform technologies-such as high-throughput ligand screening, cryo-EM optimization, and cell-based functional assays-serves as a differentiator that can de-risk multiple programs simultaneously. Moreover, companies focused on rare or orphan receptor biology are increasingly using precision biomarkers and adaptive trial designs to enhance signal detection and to create clearer regulatory pathways.
The most successful organizations combine deep scientific insight with disciplined portfolio management, structured partnership frameworks, and scalable operational capabilities that allow them to pivot rapidly as translational data emerge. This hybrid model reduces execution risk and positions companies to capitalize on emerging therapeutic opportunities across GPCR classes and indications.
Practical, high-impact actions for leaders to synchronize discovery priorities, translational rigor, and operational resilience to accelerate GPCR program success
Industry leaders can adopt targeted actions to convert scientific momentum into sustained clinical and commercial outcomes. First, align discovery agendas with robust translational hypotheses and invest in orthogonal validation methods to ensure targets have clear mechanistic links to disease pathophysiology. Second, integrate biomarker strategies and companion diagnostic planning early in program design to enhance signal detection and to facilitate regulatory interactions. Third, diversify modality portfolios to include small molecules, biologics, and emerging delivery mechanisms, balancing risk across approaches that may unlock distinct therapeutic advantages.
Operationally, firms should strengthen supplier relationships and scenario-plan for supply chain disruptions to mitigate exposure to procurement shocks and potential tariff impacts. Strategic partnerships with specialist CROs and diagnostic developers can accelerate capability acquisition without necessitating full internal build-out. Additionally, investing in cross-functional teams that bridge discovery, translational science, and clinical development will improve decision velocity and ensure that go/no-go determinations are based on integrated evidence.
Finally, cultivate adaptive clinical designs and real-world evidence frameworks that reduce late-stage attrition and enable earlier demonstration of clinical value. These combined measures will position organizations to respond nimbly to scientific advances, regulatory evolution, and commercial imperatives within the GPCR landscape.
A rigorous, multi-source research methodology combining literature synthesis, expert interviews, and cross-validation to ensure dependable insights into GPCR science and strategy
The research methodology underpinning this executive analysis combines a structured review of primary scientific literature, synthesis of translational case studies, and qualitative interviews with subject-matter experts across discovery, clinical development, and diagnostics. Technical validation relied on cross-referencing structural biology publications, assay development reports, and peer-reviewed translational studies to ensure mechanistic fidelity in target characterization. Insights into operational and commercial dynamics were informed by practitioner interviews with drug developers, CRO leaders, and diagnostic innovators to capture real-world challenges and adaptive strategies.
To ensure robustness, thematic findings were triangulated through comparative analysis across therapeutic areas and receptor classes, highlighting recurring patterns and divergent approaches. Regional and supply chain assessments were developed by analyzing regulatory guidance, clinical trial landscape signals, and publicly available manufacturing trends to contextualize strategic implications. Throughout, the methodology emphasized transparency of assumptions, the use of multiple evidence streams, and validation against expert opinion to provide a reliable basis for the recommendations and strategic observations presented in this summary.
Concise synthesis of scientific, operational, and strategic imperatives that will determine which GPCR programs advance successfully from discovery to clinical impact
In summary, the GPCR domain is experiencing a dynamic phase in which technological advances, translational rigor, and strategic collaborations are unlocking new therapeutic possibilities. Progress in structural characterization, biomarker integration, and modality innovation is enabling more targeted and potentially safer interventions across a broad range of indications. At the same time, operational realities-such as supply chain resilience and regional regulatory complexity-require proactive planning and flexible execution models.
Stakeholders that succeed will be those who marry deep scientific insight with disciplined portfolio and partnership strategies, invest in platform capabilities that de-risk multiple programs, and adopt adaptive clinical and commercial approaches to demonstrate value. By aligning discovery priorities with translational evidence and by strengthening operational resilience, organizations can navigate the shifting landscape and capture opportunities that emerge at the intersection of receptor biology and patient need. The cumulative effect of these actions is a more efficient pathway from receptor insight to therapeutic impact.
Note: PDF & Excel + Online Access - 1 Year
How converging breakthroughs in structural biology, computational modeling, and translational platforms are reshaping GPCR therapeutic strategies and program prioritization
The field of G-protein coupled receptors (GPCRs) sits at a pivotal inflection point where basic discovery converges with translational ambition. Over the past decade, incremental advances in structural biology, cryo-electron microscopy, and high-resolution ligand screening have converged with computational modeling and phenotypic screening to create a more navigable target landscape. As a result, drug discovery teams are moving beyond traditional orthosteric antagonism toward nuanced modulation strategies that include biased agonism, allosteric modulation, and ligand-directed signaling. These shifts are not merely technical; they are reshaping therapeutic hypotheses and enabling new modality classes to enter early development.
In parallel, the ecosystem supporting GPCR research has matured. Contract research organizations, academic centers, and specialized diagnostic labs are deploying integrated platforms to accelerate target validation and compound progression. This has increased the throughput of translational pipelines and shortened the interval between target identification and clinical testing. Consequently, stakeholders must adapt both scientific frameworks and operational models to capture value. Investment decisions now hinge on the ability to translate molecular insights into clinically meaningful endpoints, while navigating regulatory expectations and payer scrutiny. The interplay of enabling technologies, collaborative frameworks, and strategic prioritization defines the contemporary GPCR narrative and will determine which programs advance most successfully into late-stage development.
Key technological, translational, and commercial inflection points that are fundamentally altering GPCR program strategies and collaborative models across drug development
The GPCR landscape is experiencing transformative shifts driven by several catalytic forces that together redefine competitive advantage. First, technological maturation in structural and biophysical methods has unlocked receptor conformations previously inaccessible, prompting discovery teams to revisit long-dormant target classes and to design more selective modulators. Second, advances in single-cell and spatial omics are providing richer disease context and receptor expression maps, allowing researchers to prioritize targets with clearer mechanistic links to clinical phenotypes. Third, the rise of precision medicine frameworks has elevated the importance of biomarkers and companion diagnostics, which are increasingly integrated into early-phase programs to derisk late-stage development.
These trends are accompanied by evolving modality mixes, where small molecules, peptides, and biologics are complemented by innovative delivery approaches and intracellular targeting strategies. The commercial landscape is also shifting as partnerships between biopharma and specialized technology providers accelerate, and as investors place a premium on programs that demonstrate differentiated mechanisms or clear paths to biomarker-driven endpoints. Together, these dynamics are reshaping priorities across discovery, preclinical development, and clinical trial design, and they are prompting organizations to reassess talent, infrastructure, and partnership models to remain competitive in a rapidly evolving field.
Anticipating how tariff-driven shifts to supply chains, procurement choices, and clinical operations will influence GPCR program timelines and strategic sourcing decisions
The introduction of tariffs and changes to trade policy can exert multifaceted effects on the lifecycle of GPCR-focused programs, with consequences that ripple from procurement through clinical operations. Increased tariffs on imported reagents, laboratory instrumentation, and specialized consumables can raise operational costs for discovery and preclinical labs, prompting procurement teams to explore alternative suppliers, to accelerate inventory hedging, or to localize sourcing to mitigate exposure. These procurement dynamics can, in turn, influence the timing and throughput of screening campaigns and in vivo studies.
For clinical development, tariffs that affect the cost or availability of devices, diagnostic reagents, or outsourced services can complicate global trial execution and site selection. Sponsors may face higher per-patient operational costs, longer lead times for specialized equipment, and increased complexity in managing cross-border logistics for biological samples. CROs and service providers confronted with elevated input costs may pass these onto sponsors or restructure contracts, adding negotiation friction and potentially altering program budgets and timelines.
Longer term, tariff-driven cost pressures can incentivize reshoring of manufacturing and support services, investment in domestic supply chains, and consolidation among vendors that can absorb incremental costs. While tariff policy is only one of several factors shaping program economics, it materially alters strategic deliberations around outsourcing, localization, and portfolio sequencing for teams advancing GPCR-targeted therapies into clinical development.
Detailed segmentation insights that connect receptor classes, therapeutic focus areas, development applications, and end-user profiles to strategic research and commercial priorities
Segment-level granularity illuminates where scientific opportunity and commercial necessity intersect within the GPCR ecosystem. Analysis by receptor class highlights the prominence of Class A rhodopsin receptors, which are explored through subtypes such as amino acid receptors, chemokine receptors, lipid receptors, monoamine receptors, opsin receptors, and peptide receptors, while Class B secretin, Class C metabotropic glutamate, Class F frizzled/taste 2, and orphan receptors expand the horizon for novel mechanisms. This receptor-centric framework supports target prioritization by correlating structural tractability, disease linkage, and historical success rates.
Therapeutic area segmentation underscores the breadth of clinical applications for GPCR modulation, from cardiovascular diseases and central nervous system disorders to gastrointestinal illness, inflammatory conditions, metabolic disorders, oncology, pain management, and respiratory disease, with oncology programs further differentiated into areas such as breast cancer, colorectal cancer, leukemia, lung cancer, and prostate cancer. Mapping receptors to therapeutic indications clarifies where translational investability is strongest and where biomarker strategies are most critical.
Application-based segmentation captures the lifecycle of innovation, spanning drug discovery, preclinical development, diagnostics, and clinical trials across early to late phase development, and highlights how phase-specific needs-such as validation assays or companion biomarker deployment-shift resource allocation. Finally, end-user segmentation differentiates academic and research institutes, contract research organizations, diagnostic laboratories, and pharmaceutical and biotech companies, offering insight into where demand for specialized services, platform technologies, and collaborative partnerships will concentrate as programs advance through discovery and development.
How regional capabilities, regulatory frameworks, and clinical infrastructure across the Americas, Europe Middle East & Africa, and Asia-Pacific shape GPCR development and commercialization strategies
Regional dynamics shape the strategic choices of GPCR programs as scientific opportunity intersects with regulatory regimes, healthcare infrastructure, and investment ecosystems. In the Americas, a concentration of innovation hubs, advanced clinical research networks, and deep capital markets supports rapid progression from discovery to late-stage trials, while a mature biotech and pharmaceutical sector drives demand for specialized CROs, diagnostics, and translational services. This environment favors bold translational hypotheses and the rapid scaling of clinical programs when regulatory and reimbursement planning is integrated early.
Europe, the Middle East & Africa presents a heterogeneous landscape in which strong academic centers and industry clusters coexist with varied regulatory pathways and market access frameworks. Cross-border collaborations and pan-regional clinical trial designs are common, and the region often serves as a testing ground for biomarker-driven development strategies that require sophisticated diagnostics. Meanwhile, Asia-Pacific exhibits rapid growth in R&D investment, an expanding talent base, and increasing capabilities in both discovery and manufacturing. Emerging markets in this region can offer cost-effective clinical trial capacity and manufacturing scale, yet stakeholders must carefully navigate local regulatory expectations and infrastructure variances.
These regional contrasts inform decisions about site selection, partnership models, and commercialization sequencing, and they emphasize the need for a nuanced approach that aligns scientific objectives with regional capabilities and patient access considerations.
Corporate and partnership strategies that combine platform investments, biomarker integration, and agile portfolio management to accelerate GPCR discoveries toward clinical proof of concept
Companies operating across the GPCR value chain are differentiating through technology stacks, therapeutic focus, and strategic partnerships. Large pharmaceutical firms leverage broad internal capabilities to advance late-stage programs and to integrate companion diagnostics with clinical development, while nimble biotech companies often pursue high-risk, high-reward targets enabled by specialized platforms or novel modality approaches. Contract research organizations and diagnostic laboratories emphasize integrated service offerings, combining assay development, biomarker analytics, and clinical support to accelerate program timelines and reduce translational uncertainty.
Strategic collaborations are a central theme, as biopharma organizations seek external expertise in structural biology, AI-driven discovery, and specialized assay development to complement internal strengths. Investment in platform technologies-such as high-throughput ligand screening, cryo-EM optimization, and cell-based functional assays-serves as a differentiator that can de-risk multiple programs simultaneously. Moreover, companies focused on rare or orphan receptor biology are increasingly using precision biomarkers and adaptive trial designs to enhance signal detection and to create clearer regulatory pathways.
The most successful organizations combine deep scientific insight with disciplined portfolio management, structured partnership frameworks, and scalable operational capabilities that allow them to pivot rapidly as translational data emerge. This hybrid model reduces execution risk and positions companies to capitalize on emerging therapeutic opportunities across GPCR classes and indications.
Practical, high-impact actions for leaders to synchronize discovery priorities, translational rigor, and operational resilience to accelerate GPCR program success
Industry leaders can adopt targeted actions to convert scientific momentum into sustained clinical and commercial outcomes. First, align discovery agendas with robust translational hypotheses and invest in orthogonal validation methods to ensure targets have clear mechanistic links to disease pathophysiology. Second, integrate biomarker strategies and companion diagnostic planning early in program design to enhance signal detection and to facilitate regulatory interactions. Third, diversify modality portfolios to include small molecules, biologics, and emerging delivery mechanisms, balancing risk across approaches that may unlock distinct therapeutic advantages.
Operationally, firms should strengthen supplier relationships and scenario-plan for supply chain disruptions to mitigate exposure to procurement shocks and potential tariff impacts. Strategic partnerships with specialist CROs and diagnostic developers can accelerate capability acquisition without necessitating full internal build-out. Additionally, investing in cross-functional teams that bridge discovery, translational science, and clinical development will improve decision velocity and ensure that go/no-go determinations are based on integrated evidence.
Finally, cultivate adaptive clinical designs and real-world evidence frameworks that reduce late-stage attrition and enable earlier demonstration of clinical value. These combined measures will position organizations to respond nimbly to scientific advances, regulatory evolution, and commercial imperatives within the GPCR landscape.
A rigorous, multi-source research methodology combining literature synthesis, expert interviews, and cross-validation to ensure dependable insights into GPCR science and strategy
The research methodology underpinning this executive analysis combines a structured review of primary scientific literature, synthesis of translational case studies, and qualitative interviews with subject-matter experts across discovery, clinical development, and diagnostics. Technical validation relied on cross-referencing structural biology publications, assay development reports, and peer-reviewed translational studies to ensure mechanistic fidelity in target characterization. Insights into operational and commercial dynamics were informed by practitioner interviews with drug developers, CRO leaders, and diagnostic innovators to capture real-world challenges and adaptive strategies.
To ensure robustness, thematic findings were triangulated through comparative analysis across therapeutic areas and receptor classes, highlighting recurring patterns and divergent approaches. Regional and supply chain assessments were developed by analyzing regulatory guidance, clinical trial landscape signals, and publicly available manufacturing trends to contextualize strategic implications. Throughout, the methodology emphasized transparency of assumptions, the use of multiple evidence streams, and validation against expert opinion to provide a reliable basis for the recommendations and strategic observations presented in this summary.
Concise synthesis of scientific, operational, and strategic imperatives that will determine which GPCR programs advance successfully from discovery to clinical impact
In summary, the GPCR domain is experiencing a dynamic phase in which technological advances, translational rigor, and strategic collaborations are unlocking new therapeutic possibilities. Progress in structural characterization, biomarker integration, and modality innovation is enabling more targeted and potentially safer interventions across a broad range of indications. At the same time, operational realities-such as supply chain resilience and regional regulatory complexity-require proactive planning and flexible execution models.
Stakeholders that succeed will be those who marry deep scientific insight with disciplined portfolio and partnership strategies, invest in platform capabilities that de-risk multiple programs, and adopt adaptive clinical and commercial approaches to demonstrate value. By aligning discovery priorities with translational evidence and by strengthening operational resilience, organizations can navigate the shifting landscape and capture opportunities that emerge at the intersection of receptor biology and patient need. The cumulative effect of these actions is a more efficient pathway from receptor insight to therapeutic impact.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
196 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Advancements in cryo-EM guided structure-based drug design for GPCR targets
- 5.2. Emergence of biased agonists to selectively modulate GPCR signaling pathways
- 5.3. Identification and therapeutic exploration of orphan GPCR deorphanization efforts
- 5.4. Development of GPCR-targeted antibody therapies for enhanced specificity and efficacy
- 5.5. Application of artificial intelligence and machine learning to GPCR ligand discovery
- 5.6. Progress in allosteric modulator design to fine-tune GPCR receptor conformations
- 5.7. Exploitation of GPCR heteromerization for novel drug targeting and pathway biasing
- 5.8. Integration of photopharmacology approaches to achieve spatiotemporal control of GPCR activity
- 5.9. Advances in GPCR-targeted drug delivery using nanocarriers for tissue-specific engagement
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. G-Protein Coupled Receptors Market, by Receptor Class
- 8.1. Class A Rhodopsin
- 8.1.1. Amino Acid Receptors
- 8.1.2. Chemokine Receptors
- 8.1.3. Lipid Receptors
- 8.1.4. Monoamine Receptors
- 8.1.5. Opsin Receptors
- 8.1.6. Peptide Receptors
- 8.2. Class B Secretin
- 8.3. Class C Metabotropic Glutamate
- 8.4. Class F Frizzled/Taste 2
- 8.5. Orphan Receptors
- 9. G-Protein Coupled Receptors Market, by Therapeutic Area
- 9.1. Cardiovascular Diseases
- 9.2. Cns Disorders
- 9.3. Gastrointestinal Disorders
- 9.4. Inflammation
- 9.5. Metabolic Disorders
- 9.6. Oncology
- 9.6.1. Breast Cancer
- 9.6.2. Colorectal Cancer
- 9.6.3. Leukemia
- 9.6.4. Lung Cancer
- 9.6.5. Prostate Cancer
- 9.7. Pain Management
- 9.8. Respiratory Disorders
- 10. G-Protein Coupled Receptors Market, by Application
- 10.1. Clinical Trials
- 10.1.1. Phase I
- 10.1.2. Phase II
- 10.1.3. Phase III
- 10.2. Diagnostics
- 10.3. Drug Discovery
- 10.4. Preclinical Development
- 11. G-Protein Coupled Receptors Market, by End User
- 11.1. Academic And Research Institutes
- 11.2. Contract Research Organizations
- 11.3. Diagnostic Laboratories
- 11.4. Pharmaceutical And Biotech Companies
- 12. G-Protein Coupled Receptors Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. G-Protein Coupled Receptors Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. G-Protein Coupled Receptors Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Abalone Bio, Inc.
- 15.3.2. Abcam PLC
- 15.3.3. Addex Therapeutics
- 15.3.4. Becton, Dickinson and Company
- 15.3.5. BioInvenu,Inc.
- 15.3.6. Cisbio Bioassays SAS
- 15.3.7. Confo Therapeutics
- 15.3.8. Corning Incorporated
- 15.3.9. Crinetics Pharmaceuticals, Inc.
- 15.3.10. Domain Therapeutics SA
- 15.3.11. Enzo Life Sciences, Inc.
- 15.3.12. Escient Pharmaceuticals
- 15.3.13. Eurofins Scientific SE
- 15.3.14. Merck KGaA
- 15.3.15. Molecular Devices, LLC
- 15.3.16. OKYO Pharma, Limited
- 15.3.17. Orion Biotechnology
- 15.3.18. OSE Immunotherapeutics
- 15.3.19. PerkinElmer Inc.
- 15.3.20. Promega Corporation
- 15.3.21. QIAGEN GmbH
- 15.3.22. Septerna
- 15.3.23. Sosei Group Corporation
- 15.3.24. Tectonic Therapeutic
- 15.3.25. Teon Therapeutics, Inc.
- 15.3.26. Thermo Fisher Scientific Inc.
- 15.3.27. WuXi AppTec
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
